A Study of LY900020 in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 29, 2019

Primary Completion Date

February 18, 2020

Study Completion Date

February 18, 2020

Conditions

Healthy

Interventions

DRUG

LY900020

Administered orally

DRUG

Metformin XR

Administered orally

DRUG

Atorvastatin

Administered orally

DRUG

Valsartan

Administered orally

Trial Locations (1)

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT04047940 - A Study of LY900020 in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter